{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:16:46Z","timestamp":1784546206753,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T00:00:00Z","timestamp":1411776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ejca.2014.09.013","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T08:49:28Z","timestamp":1413362968000},"page":"3125-3135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme"],"prefix":"10.1016","volume":"50","clinical-trial-number":[{"clinical-trial-number":"nct00661830","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"M.","family":"Moehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Maderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schimanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kanzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Denzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.T.","family":"Kolligs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Distelrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Berie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sauvigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Dollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Lindig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lubomierski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wachtlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-K.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schadmand-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Woerns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2014.09.013_b0005","article-title":"Cancers of the biliary system","volume":"30 Spec No 2","author":"Malka","year":"2006","journal-title":"Gastroenterol Clin Biol"},{"issue":"11","key":"10.1016\/j.ejca.2014.09.013_b0010","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.bjc.6605377","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner","year":"2009","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.013_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2014.09.013_b0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.013_b0030","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1478-3231.2011.02687.x","article-title":"Targeting PDGFR-beta in cholangiocarcinoma","volume":"32","author":"Fingas","year":"2012","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.ejca.2014.09.013_b0035","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","article-title":"Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors","volume":"142","author":"Andersen","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0045","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/gast.2002.32410","article-title":"Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line","volume":"122","author":"Yoon","year":"2002","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0050","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.seminoncol.2006.04.002","article-title":"Role of Raf kinase in cancer: therapeutic potential of targeting the Raf\/MEK\/ERK signal transduction pathway","volume":"33","author":"Gollob","year":"2006","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.013_b0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ejca.2014.09.013_b0060","first-page":"1083","article-title":"Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells","volume":"63","author":"Benckert","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.013_b0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-2004-828890","article-title":"The molecular pathogenesis of cholangiocarcinoma","volume":"24","author":"Berthiaume","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.013_b0075","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.23214","article-title":"Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2","volume":"50","author":"Blechacz","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ejca.2014.09.013_b0080","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bcp.2006.12.031","article-title":"Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma","volume":"73","author":"Huether","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.013_b0085","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/liv.12168","article-title":"Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma","volume":"33","author":"Cho","year":"2013","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.ejca.2014.09.013_b0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991.x","article-title":"Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib","volume":"42","author":"Otsuka","year":"2012","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.013_b0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","article-title":"Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib","volume":"15","author":"Vincenzi","year":"2010","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.013_b0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2014.09.013_b0105","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2011.04.006","article-title":"An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer","volume":"47","author":"Moehler","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.013_b0110","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone","year":"2011","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ejca.2014.09.013_b0115","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2014.09.013_b0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00384-012-1551-2","article-title":"Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft\u2013no benefit of combination therapy","volume":"28","author":"Wehler","year":"2013","journal-title":"Int J Colorectal Dis"},{"issue":"6","key":"10.1016\/j.ejca.2014.09.013_b0125","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-12-3041","article-title":"Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.013_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/1535-7163.MCT-13-0637","article-title":"Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth","volume":"13","author":"Collet","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ejca.2014.09.013_b0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/jjco\/hyq111","article-title":"Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients","volume":"40","author":"Seo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2014.09.013_b0140","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2014.09.013_b0145","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2014.09.013_b0150","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.013_b0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.013_b0160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2011.11.017","article-title":"A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study","volume":"48","author":"Thongprasert","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2014.09.013_b0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study","volume":"11","author":"Zhu","year":"2009","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2014.09.013_b0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2014.09.013_b0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino","year":"2010","journal-title":"BMC Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914009630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804914009630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:20:53Z","timestamp":1760732453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804914009630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0959804914009630"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2014.09.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2014.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}